SCHEMBL3032708

SCHEMBL3032708

Cc1nc(Br)c(C(=O)O)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.37
HSP90AA1 P07900 1/20 0.37
ESR2 Q92731 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CSNK2A1 P68400 1/20 0.33
JAK2 O60674 1/20 0.32
THRB P10828 1/20 0.32
DHODH Q02127 3/20 0.32
PIN1 Q13526 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C19 P33261 2/20 0.32
MAPK1 P28482 1/20 0.32
CASP1 P29466 1/20 0.32
HCAR2 Q8TDS4 1/20 0.31
HPGD P15428 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 2/20 0.30
POLB P06746 2/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL10790740 0.81 CYP1A2 (0.36) CSNK2A1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL16210782 0.78 KDM4C (0.42) TDP1CSNK2A1MAPK1HPGDSMN1; SMN2
SCHEMBL3023228 0.77 HSP90AA1 (0.39) GPR35HSP90AA1ESR2TDP1DHODH
SCHEMBL213561 0.76 PIN1 (0.48) HSP90AA1ESR2TDP1PIN1CYP1A2
SCHEMBL24283847 0.75 ALDH1A1 (0.50) CYP1A2CYP2C19MAPK1HPGDKDM4E
SCHEMBL3023200 0.74 ALDH1A1 (0.38) GPR35HSP90AA1ESR2TDP1CSNK2A1
SCHEMBL7416029 0.71 CYP1A2 (0.30) GPR35PIN1CYP1A2CYP2C19MAPK1
SCHEMBL948852 0.71 GABRP (0.41) HSP90AA1ESR2TDP1PIN1HCAR2
SCHEMBL8077442 0.71 PIN1 (0.37) HSP90AA1ESR2TDP1DHODHPIN1
SCHEMBL8652103 0.71 GAA (0.43) HSP90AA1ESR2TDP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 GPR35 4091/4885HSP90AA1 3584/4885ESR2 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.